Top Markets
Coin of the day
Hillstream BioPharma, Inc. Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS
Rangering i aksjer #37089
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed... Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Aksjekurs
$0.181
Sist synkronisert: 2023-10-20
Markedsverdi
$2.03M
Endring (1 dag)
-9.45%
Endring (1 år)
0.00%
Land
US
Handel Hillstream BioPharma, Inc. (HILS)

Kategori

Utbytteavkastning for Hillstream BioPharma, Inc. (HILS)
Hillstream BioPharma, Inc. (aksjesymbol: HILS) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Hillstream BioPharma, Inc. (HILS) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter